Molecular Clamp Technology
Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines
Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines
Vicebio Secures $100 Million Funding to Advance Multivalent Respiratory Virus Vaccines
Vicebio, Multivalent Respiratory Virus Vaccines, $100 Million Funding, Series B Funding Round, Molecular Clamp Technology, RSV and hMPV Vaccine Combo